jRCT2071230041已完成不适用
A single- and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of KP-910 in healthy adult males and healthy elderly males.
Kaken Pharmaceutical Co. Ltd.0 个研究点目标入组 96 人开始时间: 2023年8月4日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 主要终点
- Safety
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age 0month old over 至 No limit（—）
- 性别
- Male
入选标准
- •Japanese male aged 18 to 55 years old at the time of consent. For the step for elderly subjects, Japanese male aged 65 years or older at the time of consent
- •Male whose weight at screening is 50.0 kg or over.
- •Male whose BMI at screening is between 18.0 and 25.0
排除标准
- •Diagnosed as difficult to participate in the clinical trial because of a problem with ensuring the safety of the subject who has disorders or a history of the central nervous system, heart disease, circulatory system, respiratory system, blood/hematopoietic system, gastrointestinal system, liver/renal system, thyroid function, pituitary function, adrenal function, etc.
- •Diagnosed as difficult to participate in the clinical trial because of a problem with ensuring the safety of the subject who has symptoms or a history of dizziness or lightheadedness.
- •Diagnosed as having the potential to affect pharmacokinetics because of a history of surgical procedures or medical conditions.
- •Subjects who have used or will need to use the drug within 14 days prior to administration of the investigational drug.
- •Subjects who have administered or will need to administer a therapy within 14 days prior to administration of the investigational drug.
- •Subjects who have consumed citrus fruits (grapefruit, pomelo, dai dai, etc.) or foods or beverages containing high levels of furanocoumarins within 72 hours prior to the administration of the investigational drug.
- •Subjects who habitually consume excessive amounts of alcohol (guideline: average daily intake of more than 1.3 L of beer or 360 mL of sake).
- •Subjects who habitually consume more than 6 cups (1 cup: 150 mL) of coffee, black tea, green tea, cola, or other caffeine-containing beverages per day
- •Subjects who are heavy smokers (approximately more than the equivalent of 10 cigarettes per day).
- •Subjects who underwent blood sampling more than 400 mL within 12 weeks (84 days) prior to administration of the investigational drug, blood sampling more than 200 mL within 4 weeks (28 days) prior to administration of the investigational drug, or blood component donation within 2 weeks (14 days) prior to administration of the investigational drug, or whose total annual blood volume exceeds 1200 mL including planned blood sampling volume for this clinical trial.
- •Subjects who received another investigational product within 16 weeks (112 days) prior to receiving the investigational product.
- •Subjects who have a history of allergy to any drug or have any other special physical condition (e.g., hypersensitivity to alcohol).
- •Subjects who have drug dependence (narcotics, stimulants, psychotropic drugs, etc.) or alcohol dependence, or those with a history of such dependence.
- •Subjects who test positive for drugs of abuse in urine at screening.
- •Diagnosed with QTcF > 450 msec or clinically significant ECG abnormality on 12-lead electrocardiogram at screening.
- •Subjects with positive immunological tests (HIV antigen/antibody, HBs antigen, HCV antibody, syphilis) at screening
- •Subjects with a positive SARS-Cov2 test on the day of admission
- •Employees of Kaken Pharmaceutical Co. Ltd., principal (sub) investigator medical institution staff under the direct supervision of the investigators, or CRO staff involved in this study
- •In the case of elderly subjects, those whose estimated creatinine clearance (Cockcroft-Gault formula) is less than 60 mL/min at screening
结局指标
主要结局
Safety
Physical examination, vital signs, laboratory tests, 12-lead electrocardiogram, echocardiography, C-SSRS
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.ACTRN12620000583943Senz Oncology Pty Ltd50
进行中（未招募）
不适用
first in man study with CetuGEX in patients with metastatic cancerHistologically confirmed locally advanced and/or metastatic solid organ tumourMedDRA version: 14.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019552-50-DEGlycotope GmbH85
招募中
1 期
A single- and multiple ascending dose study of KP-910 in healthy adult males and healthy elderly males.JPRN-jRCT2071230041Murakami Harumi96
已完成
不适用
A dose response study of the effects of increased fruit and vegetables intake on vascular functioISRCTN50011192Food Standards Agency (UK)48
已完成
1 期
Phase1 study of GT-02037 in Healthy VolunteersHealthy adult subjectsJPRN-jRCT2080225152GlyTech, Inc.48